ECSP19000167A - Métodos y composiciones para el tratamiento de la hipercalciuria y la nefrolitiasis - Google Patents

Métodos y composiciones para el tratamiento de la hipercalciuria y la nefrolitiasis

Info

Publication number
ECSP19000167A
ECSP19000167A ECSENADI2019167A ECDI201900167A ECSP19000167A EC SP19000167 A ECSP19000167 A EC SP19000167A EC SENADI2019167 A ECSENADI2019167 A EC SENADI2019167A EC DI201900167 A ECDI201900167 A EC DI201900167A EC SP19000167 A ECSP19000167 A EC SP19000167A
Authority
EC
Ecuador
Prior art keywords
hypercalciuria
nephrolithiasis
compositions
methods
treatment
Prior art date
Application number
ECSENADI2019167A
Other languages
English (en)
Inventor
Eduardo Canto
Original Assignee
Ana Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ana Pharmaceuticals Inc filed Critical Ana Pharmaceuticals Inc
Publication of ECSP19000167A publication Critical patent/ECSP19000167A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pediatric Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se describen métodos, composiciones y formulaciones para tratar o prevenir la hipercalciuria, reduciendo así el riesgo de nefrolitiasis y normalizando la composición química y la composición de la orina. El método incluye administrar vitamina K2 en una composición medicinal o nutricional, preferiblemente sin calcio, opcionalmente en combinación con una dosis terapéutica de uno o más seleccionados del grupo que consiste en: una sal de citrato, óxido de magnesio, una sal de bicarbonato y vitamina B6.
ECSENADI2019167A 2016-06-02 2019-01-02 Métodos y composiciones para el tratamiento de la hipercalciuria y la nefrolitiasis ECSP19000167A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662344653P 2016-06-02 2016-06-02

Publications (1)

Publication Number Publication Date
ECSP19000167A true ECSP19000167A (es) 2019-01-31

Family

ID=60479095

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI2019167A ECSP19000167A (es) 2016-06-02 2019-01-02 Métodos y composiciones para el tratamiento de la hipercalciuria y la nefrolitiasis

Country Status (14)

Country Link
US (1) US20200315233A1 (es)
EP (1) EP3463322A4 (es)
JP (2) JP2019517482A (es)
AU (1) AU2017274438A1 (es)
BR (1) BR112018075067A2 (es)
CA (1) CA3026143A1 (es)
CO (1) CO2018013999A2 (es)
CR (1) CR20180576A (es)
DO (1) DOP2018000265A (es)
EC (1) ECSP19000167A (es)
MX (2) MX2018014933A (es)
NI (1) NI201800126A (es)
TW (1) TW201808271A (es)
WO (1) WO2017210467A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109806225B (zh) * 2019-03-16 2021-06-01 西安安健药业有限公司 维生素k1脂肪乳注射液
CN112438967A (zh) * 2019-08-27 2021-03-05 高兵 维生素k在制备泌尿系结石防治药物和保健品中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4446024C2 (de) * 1994-12-22 1997-01-23 Bartz Volker Verwendung eines Vitamins der K-Gruppe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
CN1322530A (zh) * 2000-05-09 2001-11-21 詹炳炎 一种防治泌尿系结石的药物——尿石净
US7758893B2 (en) * 2001-07-27 2010-07-20 N.V. Nutricia Enteral compositions for the prevention and/or treatment of sepsis
US20050233461A1 (en) * 2002-06-05 2005-10-20 Douglas Levinson High-throughput methods and systems for screening of compounds to treat/prevent kidney disorders
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
US20080220094A1 (en) * 2006-11-01 2008-09-11 Wyeth Compositions and methods for the treatment and/or prevention of osteoporosis
MX2010000927A (es) * 2007-07-24 2010-05-19 Viridis Biopharma Pvt Ltd Uso de analogos y derivados de la vitamina k para el tratamiento de transtornos y condiciones de enfermedad en humanos.
DK2477510T3 (en) * 2009-09-14 2018-05-28 Nestec Sa FOOD COMPOSITIONS FOR MODULATING INFLAMMATION INCLUDING EXOGENT VITAMIN K2
US20110229587A1 (en) * 2009-09-24 2011-09-22 Algaecal Distribution Inc. Calcium Supplements for the Treatment of Diabetes
EP2601168A4 (en) * 2010-08-06 2013-12-04 Ampere Life Sciences Inc TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K
WO2012170773A1 (en) * 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
US20150359807A1 (en) * 2014-06-11 2015-12-17 Supernutrition Life-Extension Research, Inc. Dietary Supplement Containing Vitamin A, D3 and Vitamin K2 and Uses Thereof

Also Published As

Publication number Publication date
EP3463322A1 (en) 2019-04-10
MX2022013681A (es) 2022-12-13
EP3463322A4 (en) 2019-11-20
TW201808271A (zh) 2018-03-16
MX2018014933A (es) 2019-04-09
NI201800126A (es) 2019-03-28
CO2018013999A2 (es) 2019-03-08
JP2022153651A (ja) 2022-10-12
JP2019517482A (ja) 2019-06-24
WO2017210467A1 (en) 2017-12-07
US20200315233A1 (en) 2020-10-08
CR20180576A (es) 2019-04-09
AU2017274438A1 (en) 2018-12-13
DOP2018000265A (es) 2019-04-30
BR112018075067A2 (pt) 2019-04-30
CA3026143A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
SG10201811185YA (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
CL2018000739A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma.
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
SG10201902664RA (en) Combination therapy for treating cancer
AR105712A1 (es) Composiciones de insulina de rápida acción
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
ECSP18080294A (es) Métodos de tratamiento con vitamina d
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112016026545A8 (pt) eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
CO2019003865A2 (es) Proteína terapéutica
ECSP19000167A (es) Métodos y composiciones para el tratamiento de la hipercalciuria y la nefrolitiasis
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
BR112016029437A2 (pt) métodos para tratamento e prevenção de doenças de instabilidade vascular
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
AR102308A1 (es) Composición farmacéutica para usar en el tratamiento o prevención de deficiencias de vitaminas y minerales en pacientes sometidos a cirugía de bypass gástrico
BR112017019480A2 (pt) dosagem unitária de composição vitamínica ampliável, e, método para tratar uma deficiência de vitamina lipossolúvel.
AR101673A1 (es) Composición para el tratamiento de neuropatías y del dolor neuropático
GB2550750A (en) Anthelmintic compounds
CO2021005797A2 (es) Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
BR112018002433A2 (pt) composição farmacêutica para tratamento da enxaqueca
MX2017014731A (es) Eliminacion de linfocitos b como marcador diagnostico.
MX2016013889A (es) Medicamento.